Natco Pharma, Celgene ink pact for cancer treatment drug Lenalidomide
Lenalidomide is used to treat various types of cancers.
New Delhi: Natco Pharma on Friday said its Canadian subsidiary has entered into a settlement agreement with biopharmaceutical firm Celgene (part of Bristol-Myers Squibb) for Lenalidomide capsules. Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells."Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd has entered...
New Delhi: Natco Pharma on Friday said its Canadian subsidiary has entered into a settlement agreement with biopharmaceutical firm Celgene (part of Bristol-Myers Squibb) for Lenalidomide capsules.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells.
"Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada," the company said in a regulatory filing.
The terms of the agreement are confidential as per the agreement, the company added.
Shares of Natco Pharma were trading 0.15 per cent lower at Rs 676.50 apiece on BSE.
Read also: COVID 19: Natco Pharma supports Columbia University trials for CQ tablets to prevent infections
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd